Clinical Trial

Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

Study acronym: miRNA-NAC
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-04; most recent amendment 2026-03-30.
Status change: Not Yet Recruiting → Recruiting 2026-03-30
Trial Details
NCT Number NCT07289282
Lead Sponsor Atlas University
Conditions Breast Cancer, Neoadjuvant Therapy, Pathological Response, Invasive Breast Carcinoma, MicroRNAs
Enrollment 80 participants
Start Date 2025-12-15
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-31